21 – 30 of 169
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
(
- Contribution to journal › Article
-
Mark
Longitudinal changes in risk status in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Underfilling decreases left ventricular function in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis : The UPSIDE study protocol
(
- Contribution to journal › Article
-
Mark
Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival
(
- Contribution to journal › Article
-
Mark
Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension : call for a refined assessment
(
- Contribution to journal › Article
-
Mark
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews
(
- Contribution to journal › Article
- 2020
-
Mark
Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis
(
- Contribution to journal › Article
-
Mark
Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
(
- Contribution to journal › Article